nadolol ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
beta-adrenoreceptor antagonists 1865 42200-33-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nadolol
  • corgard
  • anabet
  • solgol
A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.
  • Molecular weight: 309.41
  • Formula: C17H27NO4
  • CLOGP: 0.38
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 81.95
  • ALOGS: -2.14
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.16 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2.25 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 73 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 34.58 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.14 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 10, 1979 FDA KING PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 932.65 15.07 293 11672 24083 63452974
Chronic sinusitis 195.54 15.07 78 11887 12765 63464292
Paraesthesia oral 159.03 15.07 76 11889 19180 63457877
Procedural pain 150.84 15.07 76 11889 21493 63455564
Neovascularisation 148.48 15.07 36 11929 1109 63475948
Drug ineffective 135.46 15.07 466 11499 1044299 62432758
Dyspepsia 128.52 15.07 125 11840 102071 63374986
Weight decreased 115.15 15.07 195 11770 276603 63200454
Vaginal flatulence 102.78 15.07 34 11931 3259 63473798
Paradoxical drug reaction 102.67 15.07 36 11929 4116 63472941
Proctitis 86.11 15.07 34 11931 5407 63471650
Female genital tract fistula 75.33 15.07 34 11931 7525 63469532
Rectal haemorrhage 75.12 15.07 67 11898 48963 63428094
Vaginal discharge 71.96 15.07 35 11930 9163 63467894
Radiculopathy 71.10 15.07 34 11931 8577 63468480
Therapeutic product effect incomplete 68.34 15.07 100 11865 124956 63352101
Extrapyramidal disorder 67.91 15.07 38 11927 13246 63463811
Anuria 67.17 15.07 37 11928 12514 63464543
Drug ineffective for unapproved indication 59.13 15.07 50 11915 34013 63443044
Frequent bowel movements 57.74 15.07 42 11923 22980 63454077
Hepatic cirrhosis 50.70 15.07 40 11925 24694 63452363
Migraine 49.85 15.07 78 11887 103268 63373789
Oral candidiasis 44.87 15.07 36 11929 22762 63454295
Colitis ulcerative 44.67 15.07 38 11927 26053 63451004
Varices oesophageal 44.03 15.07 18 11947 3130 63473927
Abdominal pain 37.51 15.07 131 11834 293325 63183732
Arthropathy 33.25 15.07 3 11962 234789 63242268
Ear congestion 32.63 15.07 14 11951 2745 63474312
Hyperplastic cholecystopathy 31.03 15.07 7 11958 156 63476901
Infusion related reaction 30.83 15.07 109 11856 245412 63231645
Hypophosphataemia 29.00 15.07 21 11944 11405 63465652
Ligament sprain 26.87 15.07 21 11944 12779 63464278
Colitis 26.75 15.07 39 11926 48489 63428568
Systemic lupus erythematosus 26.28 15.07 4 11961 208914 63268143
Haematochezia 25.22 15.07 40 11925 53504 63423553
Electrocardiogram QT prolonged 24.70 15.07 42 11923 59488 63417569
Contraindicated product administered 23.54 15.07 6 11959 217642 63259415
Malaise 23.38 15.07 146 11819 415808 63061249
Abdominal discomfort 23.28 15.07 16 11949 320869 63156188
Synovitis 22.57 15.07 4 11961 186914 63290143
Withdrawal syndrome 22.39 15.07 23 11942 19974 63457083
Oligohydramnios 21.60 15.07 14 11951 6352 63470705
Ascites 21.39 15.07 32 11933 40696 63436361
Open reduction of fracture 21.01 15.07 8 11957 1154 63475903
Wound 20.82 15.07 3 11962 163260 63313797
Intraventricular haemorrhage neonatal 19.97 15.07 5 11960 176 63476881
Hypomagnesaemia 18.67 15.07 25 11940 28712 63448345
Hypoglycaemia neonatal 18.67 15.07 7 11958 968 63476089
Splenomegaly 18.58 15.07 16 11949 11141 63465916
Long QT syndrome 18.46 15.07 10 11955 3269 63473788
Joint swelling 18.17 15.07 21 11944 327645 63149412
Portal vein thrombosis 17.59 15.07 9 11956 2621 63474436
Hepatorenal failure 17.09 15.07 6 11959 688 63476369
Oesophageal varices haemorrhage 17.07 15.07 7 11958 1227 63475830
Diarrhoea 16.80 15.07 207 11758 715159 62761898
Gastrointestinal haemorrhage 16.77 15.07 43 11922 81133 63395924
Convulsive threshold lowered 16.68 15.07 5 11960 347 63476710
Bradycardia 16.40 15.07 40 11925 73187 63403870
Alopecia 16.28 15.07 24 11941 337512 63139545
Blood uric acid decreased 16.25 15.07 6 11959 795 63476262
Maternal exposure during pregnancy 15.91 15.07 11 11954 220051 63257006
Anaemia 15.84 15.07 102 11863 293328 63183729
Hypertrophy 15.57 15.07 5 11960 436 63476621
Aphthous ulcer 15.54 15.07 16 11949 13922 63463135
Cardio-respiratory distress 15.53 15.07 4 11961 158 63476899
Cardiogenic shock 15.50 15.07 18 11947 17914 63459143
Blood albumin increased 15.14 15.07 6 11959 963 63476094
Nausea 15.09 15.07 235 11730 854236 62622821

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic encephalopathy 94.72 17.10 45 5010 14640 34937236
Varices oesophageal 67.53 17.10 24 5031 3731 34948145
Ascites 47.35 17.10 45 5010 46526 34905350
Hepatic cirrhosis 47.08 17.10 30 5025 17284 34934592
Hepatic failure 46.27 17.10 39 5016 34492 34917384
Oesophageal varices haemorrhage 41.44 17.10 16 5039 3130 34948746
Hypoglycaemia 37.87 17.10 43 5012 54597 34897279
Lactic acidosis 34.19 17.10 33 5022 34739 34917137
Bradycardia 32.70 17.10 47 5008 75371 34876505
Portal hypertensive gastropathy 32.48 17.10 9 5046 618 34951258
Ammonia increased 30.03 17.10 14 5041 4355 34947521
Chronic hepatic failure 24.90 17.10 7 5048 507 34951369
Sinus arrest 23.45 17.10 9 5046 1731 34950145
Hyperkalaemia 22.71 17.10 38 5017 69351 34882525
Acute kidney injury 20.73 17.10 93 4962 304895 34646981
Inability to afford medication 17.68 17.10 7 5048 1463 34950413
Hypotension 17.67 17.10 71 4984 221578 34730298

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 193.03 14.39 74 14515 11222 79718577
Chronic sinusitis 186.25 14.39 75 14514 12951 79716848
Paraesthesia oral 150.70 14.39 74 14515 20397 79709402
Neovascularisation 146.54 14.39 36 14553 1209 79728590
Procedural pain 142.29 14.39 74 14515 23010 79706789
Dyspepsia 123.22 14.39 124 14465 108563 79621236
Vaginal flatulence 107.73 14.39 33 14556 2542 79727257
Weight decreased 93.88 14.39 203 14386 354995 79374804
Varices oesophageal 90.84 14.39 36 14553 5955 79723844
Paradoxical drug reaction 84.52 14.39 36 14553 7149 79722650
Hepatic cirrhosis 83.15 14.39 61 14528 34845 79694954
Female genital tract fistula 80.58 14.39 33 14556 5942 79723857
Proctitis 78.23 14.39 33 14556 6399 79723400
Vaginal discharge 76.71 14.39 34 14555 7429 79722370
Hepatic encephalopathy 75.77 14.39 50 14539 24116 79705683
Radiculopathy 74.33 14.39 35 14554 8789 79721010
Therapeutic product effect incomplete 65.25 14.39 103 14486 141542 79588257
Migraine 63.26 14.39 79 14510 87414 79642385
Rectal haemorrhage 60.19 14.39 72 14517 76228 79653571
Ascites 59.11 14.39 71 14518 75491 79654308
Anuria 53.02 14.39 38 14551 20925 79708874
Oesophageal varices haemorrhage 52.40 14.39 22 14567 4214 79725585
Extrapyramidal disorder 50.35 14.39 38 14551 22641 79707158
Drug ineffective for unapproved indication 46.53 14.39 52 14537 51186 79678613
Frequent bowel movements 43.52 14.39 39 14550 29500 79700299
Hypoglycaemia 41.50 14.39 70 14519 101524 79628275
Colitis ulcerative 39.97 14.39 40 14549 34702 79695097
Oral candidiasis 37.61 14.39 36 14553 29592 79700207
Hepatic failure 36.06 14.39 50 14539 61162 79668637
Infusion related reaction 35.96 14.39 108 14481 230129 79499670
Ammonia increased 34.64 14.39 20 14569 7615 79722184
Portal hypertensive gastropathy 34.31 14.39 12 14577 1402 79728397
Open reduction of fracture 33.02 14.39 8 14581 253 79729546
Ear congestion 32.27 14.39 14 14575 2905 79726894
Abdominal pain 31.62 14.39 148 14441 389421 79340378
Hyperplastic cholecystopathy 29.06 14.39 7 14582 216 79729583
Ligament sprain 28.65 14.39 22 14567 13442 79716357
Inability to afford medication 26.47 14.39 12 14577 2761 79727038
Bradycardia 26.47 14.39 69 14520 135488 79594311
Lactic acidosis 25.50 14.39 46 14543 70313 79659486
Portal vein thrombosis 23.12 14.39 14 14575 5813 79723986
Hepatic cancer 21.95 14.39 17 14572 10512 79719287
Torsade de pointes 21.78 14.39 22 14567 19290 79710509
Splenomegaly 20.46 14.39 22 14567 20732 79709067
Arthropathy 20.06 14.39 4 14585 177107 79552692
Intramedullary rod insertion 19.83 14.39 5 14584 187 79729612
Anaemia 19.67 14.39 144 14445 444871 79284928
Hyperkalaemia 19.11 14.39 55 14534 114343 79615456
Diarrhoea 18.64 14.39 244 14345 880245 78849554
Haematochezia 18.55 14.39 46 14543 87599 79642200
Oligohydramnios 18.37 14.39 10 14579 3402 79726397
Sinus arrest 17.81 14.39 10 14579 3612 79726187
Hypophosphataemia 17.71 14.39 20 14569 19893 79709906
Hypoglycaemic unconsciousness 17.55 14.39 7 14582 1176 79728623
Gastrointestinal haemorrhage 17.39 14.39 63 14526 147656 79582143
Gastric varices 16.88 14.39 6 14583 735 79729064
Malaise 16.49 14.39 149 14440 489720 79240079
Hypoglycaemic seizure 16.26 14.39 6 14583 818 79728981
Colitis 16.07 14.39 39 14550 73268 79656531
Insurance issue 15.91 14.39 11 14578 5722 79724077
Large intestine polyp 15.30 14.39 15 14574 12693 79717106
Febrile neutropenia 15.19 14.39 12 14577 230987 79498812
Chronic hepatic failure 15.02 14.39 6 14583 1013 79728786
Electrocardiogram QT prolonged 14.65 14.39 43 14546 90343 79639456
C-reactive protein increased 14.43 14.39 3 14586 129024 79600775

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C07AA12 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
Beta blocking agents, non-selective
ATC C07BA12 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS AND THIAZIDES
Beta blocking agents, non-selective, and thiazides
FDA MoA N0000000161 Adrenergic beta-Antagonists
FDA EPC N0000175556 beta-Adrenergic Blocker
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D000319 Adrenergic beta-Antagonists
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013565 Sympatholytics
CHEBI has role CHEBI:35530 beta-adrenergic blockers
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:38070 antiarrhythmic agent
CHEBI has role CHEBI:66991 sympatholytic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Angina pectoris indication 194828000
Thyrotoxicosis off-label use 90739004 DOID:7997
Mitral valve prolapse off-label use 409712001
Essential tremor off-label use 609558009 DOID:4990
Prevention of Congenital Long QT Syndrome associated Ventricular Arrhythmia off-label use
Myocardial Reinfarction Prevention off-label use
Prevention of Bleeding Esophageal Varices off-label use
Migraine Prevention off-label use
Anuria contraindication 2472002 DOID:2983
Bronchospasm contraindication 4386001
Hypercholesterolemia contraindication 13644009
Complete atrioventricular block contraindication 27885002
Depressive disorder contraindication 35489007
Hyperuricemia contraindication 35885006 DOID:1920
Anaphylaxis contraindication 39579001
Hypokalemia contraindication 43339004
Sinus bradycardia contraindication 49710005
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Oliguria contraindication 83128009
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Hypomagnesemia contraindication 190855004
Partial atrioventricular block contraindication 195039008
Decompensated cardiac failure contraindication 195111005
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Raynaud's phenomenon contraindication 266261006
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006
Right ventricular failure contraindication 367363000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.57 acidic
pKa2 9.31 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR ANTAGONIST Ki 6.90 IUPHAR CHEMBL
Beta-2 adrenergic receptor GPCR ANTAGONIST Ki 8.60 IUPHAR CHEMBL
Beta-3 adrenergic receptor GPCR ANTAGONIST Ki 6.30 IUPHAR

External reference:

IDSource
4017603 VUID
N0000145983 NUI
D00432 KEGG_DRUG
4017603 VANDF
C0027302 UMLSCUI
CHEBI:7444 CHEBI
CHEMBL649 ChEMBL_ID
DB01203 DRUGBANK_ID
D009248 MESH_DESCRIPTOR_UI
39147 PUBCHEM_CID
554 IUPHAR_LIGAND_ID
3875 INN_ID
FEN504330V UNII
151549 RXNORM
2018 MMSL
31 MMSL
5143 MMSL
d00018 MMSL
001854 NDDF
387482003 SNOMEDCT_US
82896009 SNOMEDCT_US
220045-89-6 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nadolol and Bendroflumethiazide HUMAN PRESCRIPTION DRUG LABEL 2 0115-5311 TABLET 40 mg ORAL ANDA 25 sections
Nadolol and Bendroflumethiazide HUMAN PRESCRIPTION DRUG LABEL 2 0115-5322 TABLET 80 mg ORAL ANDA 25 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 0378-0028 TABLET 20 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 0378-0028 TABLET 20 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 0378-1132 TABLET 80 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 0378-1132 TABLET 80 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 0378-1171 TABLET 40 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 0378-1171 TABLET 40 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 0781-8004 TABLET 20 mg ORAL ANDA 21 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 0781-8004 TABLET 20 mg ORAL ANDA 21 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 0781-8005 TABLET 40 mg ORAL ANDA 21 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 0781-8005 TABLET 40 mg ORAL ANDA 21 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 0781-8006 TABLET 80 mg ORAL ANDA 21 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 0781-8006 TABLET 80 mg ORAL ANDA 21 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7070 TABLET 20 mg ORAL ANDA 18 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7071 TABLET 40 mg ORAL ANDA 18 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 10135-686 TABLET 20 mg ORAL ANDA 19 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 10135-686 TABLET 20 mg ORAL ANDA 19 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 10135-687 TABLET 40 mg ORAL ANDA 19 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 10135-687 TABLET 40 mg ORAL ANDA 19 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 10135-688 TABLET 80 mg ORAL ANDA 19 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 10135-688 TABLET 80 mg ORAL ANDA 19 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 21695-799 TABLET 40 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 21695-800 TABLET 80 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 21695-802 TABLET 20 mg ORAL ANDA 20 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 23155-730 TABLET 20 mg ORAL ANDA 12 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 23155-731 TABLET 40 mg ORAL ANDA 12 sections
Nadolol HUMAN PRESCRIPTION DRUG LABEL 1 23155-732 TABLET 80 mg ORAL ANDA 12 sections
Corgard HUMAN PRESCRIPTION DRUG LABEL 1 27505-100 TABLET 20 mg ORAL NDA 20 sections
Corgard HUMAN PRESCRIPTION DRUG LABEL 1 27505-101 TABLET 40 mg ORAL NDA 20 sections